For many years, platinum plus etoposide regimens had been recommended for patients with extensive stage small cell lung cancer (SCLC); however, the preferred regimens for extensive stage SCLC now include immune checkpoint inhibitors, either atezolizumab or durvalumab, plus platinum plus etoposide.

Education on this topic is necessary and timely, particularly as the use of advanced practice providers (APPs) is rapidly expanding. There are a variety of models that practices can use to assign work and allocate resources; however, underutilization can result in employee satisfaction issues, high burnout, and wasted resources. This activity provides guidance and best practices on utilization of APPs.

Cancer drug shortages have had a significant impact on clinical practice with much confusion around how to appropriately manage care of patients with cancer in the midst of a drug shortage. You can benefit by learning what you can do both in your practice and in your advocacy to advance short-term and long-term solutions.

As cancer centers respond to the external pressures to move more oncology care to the outpatient setting, it is important to understand the factors driving these changes and the benefits and challenges in balancing inpatient and outpatient oncology care. Safely providing high intensity oncology care in the outpatient setting can improve inpatient bed access, help reduce healthcare costs, and improve patient satisfaction.